USA flag logo/image

An Official Website of the United States Government

Role of Inter-alpha Inhibitors in Anthrax Intoxication

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
80380
Program Year/Program:
2006 / STTR
Agency Tracking Number:
AI062095
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
PROTHERA BIOLOGICS, LLC
551 Warren Avenue EAST PROVIDENCE, RI -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2006
Title: Role of Inter-alpha Inhibitors in Anthrax Intoxication
Agency: HHS
Contract: 1R41AI062095-01A2
Award Amount: $1,000,000.00
 

Abstract:

DESCRIPTION (provided by applicant): The primary goal of this proposal is to demonstrate the feasibility of utilizing Inter-alpha Inhibitor proteins (lalp) as an effective protective agent against exposure to anthrax, a lethal biological warfare agent. Inter-alpha inhibitor proteins are natural serine protease inhibitors found in relatively high concentration in human plasma. The protein complex has been shown to be important in the inhibition of serine proteases such as trypsin, elastase, plasmin and cathepsin G and has been demonstrated to play a role in immunomodulation of systemic inflammation and sepsis. In our preliminary experiments, lalp enhanced the survival of cells exposed to the lethal toxin and inhibited lethality in the experimental animals challenged with anthrax toxin in the form of protective antigen (PA) and lethal factor (LF). We have obtained evidence that lalp inhibit furin, a key enzyme that activates PA by removing a small 20 kDa fragment at the N-terminal yielding the active subunit PA63. This furin-mediated cleavage of PA is necessary for the assembly of the heptamer which mediates LF entry into the cell. We hypothesize that lalp administration will be beneficial in providing combined protection against anthrax exotoxins and in fighting sepsis which occurs in the late stage of anthrax infection. In this proposed study, we will confirm and expand our initial observations and further explore the feasibility of using the active bikunin subunit to prevent anthrax toxin induced lethality. We anticipate that these studies will ultimately lead to the development of novel strategies for management of systemic anthrax infection. Relevance: Anthrax is a lethal weapon of today's bioterrorism. Inter-alpha inhibitor proteins are natural proteins in human blood that inhibit furin, a key factor in blood cells that allows anthrax toxin to attack and destroy cells and cause septic shock, a critical condition with a high rate of death. Our research is focused on the development of a new and safe treatment based on the ability of inter-alpha proteins to prevent the fatal consequences of anthrax infection.

Principal Investigator:

Steven M. Opal
4017292545
STEVEN_OPAL@BROWN.EDU

Business Contact:

Yow-pin Lim
4013012056
PROTHERA@VERIZON.NET
Small Business Information at Submission:

PROTHERA BIOLOGICS, LLC
PROTHERA BIOLOGICS, LLC 87 WALMER AVE EAST PROVIDENCE, RI 02914

EIN/Tax ID: 710868235
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
MEMORIAL HOSPITAL OF RHODE ISLAND
MEMORIAL HOSP OF RHODE ISLAND
111 BREWSTER ST
PAWTUCKET, RI 02860
RI Type: Domestic nonprofit research organization